CMS issues final outpatient PPS rule

AHA News

The Centers for Medicare & Medicaid Services Nov. 1 announced it will update the hospital outpatient prospective payment system rates by 1.35% in calendar year 2018 compared to CY 2017. The rule also finalizes CMS’s proposal to drastically cut Medicare payment for drugs that are acquired under the 340B... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, Medicare, regulation, home health

Senators urge CMS to consider stakeholders' concerns on 340B proposal

AHA News

Fifty-seven senators Friday urged the Centers for Medicare & Medicaid Services (CMS) to “carefully consider stakeholder feedback” before the agency finalizes its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “The long-term success of the 340B program... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, advocacy, access

House lawmakers urge CMS to drop planned 340B cuts

AHA News

A bipartisan group of 228 House lawmakers yesterday urged the Centers for Medicare & Medicaid Services (CMS) to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program.

“Given the important role that the 340B program plays in our communities, we... read more

Topic: Advocacy and Public Policy
Tags: Drug Pricing Program, advocacy

CMS releases 2018 outpatient PPS and physician payment proposed rules

AHA News

The AHA July 13 criticized proposed deep cuts to how much the Centers for Medicare & Medicaid Services reimburses hospitals for drugs acquired under the 340B Drug Pricing Program and proposes changes to site-neutral payment policies under Section 603 of the 2015 Bipartisan Budget Act. The provisions are... read more

Topics: Quality and Patient Safety, Advocacy and Public Policy
Tags: 340B, site neutral payment, Drug Pricing Program, Medicare, regulation

AHA critical of MedPAC's "misdirected" 340B payment proposal

AHA News

The AHA last week criticized as “misdirected” and a blow to patient care the Medicare Payment Assessment Commission’s (MedPAC) recommendation that Congress reduce Part B drug payment rates to hospitals participating in the 340B Drug Pricing Program.

At its Jan. 14 meeting, the commission voted 14 to 3 to... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

Amid concerns of possible policy changes, hospitals brief Congress on 340B's benefits

AHA News

At an AHA-sponsored briefing Nov. 19 on Capitol Hill, hospital leaders urged Congress to protect the 340B Drug Pricing Program, and shared with congressional staff the benefits that the program brings to vulnerable patients.

“People within the communities that Trinity Health serves receive tremendous and... read more

Topics: Access and Coverage, Advocacy and Public Policy
Tags: 340B, Drug Pricing Program, access

AHA disappointed with court's ruling in 340B orphan drug case

AHA News

The AHA today expressed disappointment with a federal court decision that will exclude all drugs with an “orphan” designation from the 340B Drug Pricing Program for rural and cancer hospitals.

 AHA Executive Vice President Tom Nickels said in a statement that denying rural and cancer hospitals access to... read more

Topic: Advocacy and Public Policy
Tags: 340B, Drug Pricing Program

Rising prescription drug costs a growing concern

AHA News

The recent wave of increases in the cost of prescription drugs is straining hospital budgets and squeezing patients. 

Hospitals point to tactics like Canadian-based Valeant’s purchase earlier this year of the rights to a pair of life-saving heart medications, Isuprel and Nitropress. The day following the... read more

Topic: Advocacy and Public Policy
Tags: patient safety, Drug Pricing Program, supply chain

AHA: GAO report on 340B program misses the mark

AHA News

The AHA July 7 sharply criticized a Government Accountability Office (GAO) report examining Medicare Part B spending at disproportionate share hospitals (DSH) participating in the 340B Drug Pricing Program.

The report “draws unsubstantiated conclusions about a program that has a proven track record of... read more

Topic: Advocacy and Public Policy
Tag: Drug Pricing Program

House Energy and Commerce Committee unanimously approves 21st Century Cures Act

AHA News

The House Energy and Commerce Committee today voted 51-0 to approve H.R. 6, the 21st Century Cures Act. The cost of the $13 billion legislation is not offset by cuts in payments for hospital services – a concern that was expressed this week by the AHA in letters to the committee.

The legislation is... read more

Topic: Advocacy and Public Policy
Tags: Drug Pricing Program, EHRs, Electronic Health Records

Keyword Search

Date